Page 93 - GPD-4-3

Gene & Protein in Disease Dopaminergic dysfunction as pre-addiction

doi: 10.3390/jpm13071164 doi: 10.53043/2347-3894.acam11003
33. Blum K, Gold MS, Cadet JL, et al. Dopaminylation 41. Blum K, Gondré-Lewis MC, Baron D, et al. Introducing
in psychostimulant use disorder protects against precision addiction management of reward deficiency
psychostimulant seeking behavior by normalizing syndrome, the construct that underpins all addictive
nucleus accumbens (NAc) dopamine expression. Curr behaviors. Front Psychiatry. 2018;9:548.
Psychopharmacol. 2022;11:11-17. doi: 10.3389/fpsyt.2018.00548
doi: 10.2174/2211556009666210108112737 42. Green DR. Means to an End: Apoptosis and Other Cell Death
34. Blum K, Oscar-Berman M, Femino J, et al. Withdrawal from Mechanisms. United States: Cold Spring Harbor Laboratory
buprenorphine/naloxone and maintenance with a natural Press; 2011.
dopaminergic agonist: A cautionary note. J Addict Res Ther. 43. Böhm I, Schild H. Apoptosis: The complex scenario for a
2013;4:10.4172/2155-6105.1000146. silent cell death. Mol Imaging Biol. 2003;5:2-14.
doi: 10.4172/2155-6105.1000146 doi: 10.1016/s1536-1632(03)00024-6
35. Dennen CA, Blum K, Bowirrat A, et al. Genetic addiction 44. Alberts B. Science. Vol. 320. American Association for the
risk severity assessment identifies polymorphic reward Advancement of Science; 2008. p. 19-19.
genes as antecedents to reward deficiency syndrome (RDS)
hypodopaminergia’s effect on addictive and non-addictive 45. Karam JA. Apoptosis in Carcinogenesis and Chemotherapy.
behaviors in a nuclear family. J Pers Med. 2022;12:1864. Netherlands: Springer; 2009.
doi: 10.3390/jpm12111864 46. Alberts B, Johnson A, Lewis J, Raff M, Roberts K and
Peter W. Chapter 18: Apoptosis: Programmed cell death
36. Blum K, McLaughlin T, Modestino EJ, et al. Epigenetic eliminates unwanted cells. In: Molecular Biology of the Cell.
repair of terrifying lucid dreams by enhanced brain reward 5 ed. New York: Garland Science; 2008. p. 1115.
th
functional connectivity and induction of dopaminergic
homeostatic signaling. Curr Psychopharmacol. 2021;10:10.2 47. Elmore S. Apoptosis: A review of programmed cell death.
174/2211556010666210215153513. Toxicol Pathol. 2007;35:495-516.
doi: 10.2174/2211556010666210215153513 doi: 10.1080/01926230701320337
37. Braverman ER, Dennen CA, Gold MS, et al. Proposing a 48. Downs BW, Blum K, Baron D, et al. Death by Opioids:
Are there non-addictive scientific solutions? J Syst Integr
“brain health checkup (BHC)” as a global potential “standard
of care” to overcome reward dysregulation in primary care Neurosci. 2019;5:10.15761/JSIN.1000211.
medicine: Coupling genetic risk testing and induction of doi: 10.15761/JSIN.1000211
“dopamine homeostasis”. Int J Environ Res Public Health. 49. Hill E, Han D, Dumouchel P, et al. Long term Suboxone™
2022;19:5480.
emotional reactivity as measured by automatic detection in
doi: 10.3390/ijerph19095480 speech. PLoS One. 2013;8:e69043.
38. Bajaj A, Blum K, Bowirrat A, et al. DNA Directed pro- doi:10.1371/annotation/be0b3a26-c1bc-4d92-98c1-
dopamine regulation coupling subluxation repair, H-Wave® c516acc8dcf2
and other neurobiologically based modalities to address 50. Blum K, Chen TJ, Bailey J, et al. Can the chronic
complexities of chronic pain in a female diagnosed with administration of the combination of buprenorphine and
reward deficiency syndrome (RDS): Emergence of induction naloxone block dopaminergic activity causing anti-reward
of “dopamine homeostasis” in the face of the opioid crisis. and relapse potential? Mol Neurobiol. 2011;44:250-268.
J Pers Med. 2022;12:1416.
doi: 10.1007/s12035-011-8206-0
doi: 10.3390/jpm12091416
51. Raad M, López WO, Sharafshah A, Assefi M,
39. Gondré-Lewis MC, Elman I, Alim T, et al. Frequency of Lewandrowski KU. Personalized medicine in cancer pain
the dopamine receptor D3 (rs6280) vs. opioid receptor management. J Pers Med. 2023;13(8):1201.
µ1 (rs1799971) polymorphic risk alleles in patients with
opioid use disorder: A preponderance of dopaminergic doi: 10.3390/jpm13081201
mechanisms? Biomedicines. 2022;10:870. 52. Assefi M, Lewandrowski KU, Lorio M, et al. Network-based
doi: 10.3390/biomedicines10040870 in silico analysis of new combinations of modern drug
targets with methotrexate for response-based treatment of
40. Blum K, Green R, Mullen P, et al. Reward deficiency rheumatoid arthritis. J Pers Med. 2023;13(11):1550.
syndrome solution system (RDSSS) a genetically driven
putative inducer of “dopamine homeostasis” as a futuristic doi: 10.3390/jpm13111550
alternative to enhance rehabilitation instead of incarceration. 53. Mezher M, Abdallah S, Ashekyan O, et al. Insights on the
Asian J Complement Altern Med. 2023;11:11-14. biomarker potential of exosomal non-coding RNAs in

Volume 4 Issue 3 (2025) 11 doi: 10.36922/gpd.8090